

In vivo anti-Toxoplasma activity of aripiprazole

Mehrza Saraei^{1, 2}, Nafiseh Samadzadeh¹, Javad Khoeini¹, Mojtaba Shahnazi^{1, 2}, Marjan Nassiri-Asl^{2, 3*}, Hasan Jahanihashemi⁴

¹ Department of Medical Parasitology and Mycology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

² Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

³ Department of Pharmacology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

⁴ Department of Community Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

ARTICLE INFO

Article type:

Short communication

Article history:

Received: Sep 12, 2014

Accepted: Aug 21, 2015

Keywords:

Aripiprazole

Cysts

Toxoplasma gondii

ABSTRACT

Objective(s): There are supportive evidences about the possible role of latent *Toxoplasma gondii* infections on the behavior and neurologic functions, such as increased dopamine levels in the brain. The aim of this study was to examine anti-toxoplasma activity of aripiprazole that is an atypical anti-psychotic drug in mice.

Materials and Methods: Mice were randomly divided into four groups, including; control, vehicle, aripiprazole 10 mg/kg, and aripiprazole 20 mg/kg. The mice were inoculated intraperitoneally with mice brain suspension containing tissue cysts. At the end of second month, the number of cysts was counted in smears prepared from brain homogenate by optical microscope.

Results: There was no significant difference between mean logarithms of brain cyst numbers of aripiprazole groups compared with control.

Conclusion: Results indicate that in aripiprazole groups, the brain cystogenesis was not decrease. Further study needs to investigate the role of anti-psychotic drugs on *T. gondii*.

► Please cite this article as:

Saraei M, Samadzadeh N, Khoeini J, Shahnazi M, Nassiri-Asl M, Jahanihashemi H. In vivo anti-Toxoplasma activity of aripiprazole. Iran J Basic Med Sci 2015; 18:938-941.

Introduction

Toxoplasma gondii is a cosmopolitan obligate intracellular protozoan zoonosis which infects warm-blooded vertebrates (1). In immunocompetent hosts, cellular invasion of proliferative tachyzoites slows usually after a short period of acute phase of infection; afterwards, the parasite survives as a latent infection throughout life in tissues of hosts, especially in brain without remarkable inflammation around tissue cysts (2). The brain latent infections of *T. gondii* are considered one of the probable causative agents of chronic neurologic disorders with unknown etiology. Epidemiological studies have shown that seroprevalence of *T. gondii* is higher in patients with schizophrenia (3) in comparison to controls. Moreover, behavior and personality alterations have attributed to the chronic infections of *T. gondii* (4). Experimentally, there are evidences that support probable role of latent *T. gondii* infections in behavior and neurologic functions, such as the increasing of dopamine levels in the brain (5).

Evidence shows that some of anti-psychotic and anti-schizophrenic drugs have *in vitro* anti-toxoplasma activity. Valproic acid, an anticonvulsant mood-

stabilizer (6), and fluphenazine and thioridazine, typical anti-psychotics (7) inhibit replication of *T. gondii* RH strain tachyzoites in cell culture (8). Our aim in this study was to investigate *in vivo* anti-toxoplasma activity of aripiprazole, which is an atypical anti-psychotic drug.

Materials and Methods

Parasite

Avirulent Tehran strain of *T. gondii* was kindly prepared by the Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Iran. The strain was isolated in Iran from the lymph node aspirate of a lymphadenopathy patient (9). Mice were purchased from Razi vaccine and serum research institute, Karaj, Iran.

Animals

A total of 62 male BALB/c mice (20-25 g) were housed in groups of five per cage under standard laboratory conditions. They were kept at a constant room temperature (21±2 °C) under a normal 12L:12D regimen with free access to food and water. All animal experiments were carried out in accordance with the

*Corresponding author: Marjan Nassiri-Asl. Cellular and Molecular Research Centre, Qazvin University of Medical Sciences, Qazvin, Iran. Tel: +98-28-33336001; Fax: +98-28-33324970; email: mnassiriasl@qums.ac.ir

Table 1. Frequency of tissue cysts of *Toxoplasma gondii* in 200 µl of brain homogenate in different treatment groups of mice

Mice number in each group	Number of cysts			
	Control	Arip (LD)	Arip (HD)	Tween 80
1	1	60	322	36
2	10	51	39	27
3	16	45	41	689
4	10	31	27	50
5	27	16	32	4
6	2175	17	30	49
7	37	40	31	9
8	77	9	748	7
9	44	6	89	15
10	26	81	12	70
Mean±SEM	242.3±215.8	35.6±7.7	137.1±73.8	95.6±66.3

Arip: aripiprazole; LD: Low dose (10 mg/kg); HD: High dose (20 mg/kg); Tween 80 as vehicle

European Communities Council Directive of 24 November 1986 (86/609/EEC) in such a way as to minimize the number of animals and their suffering.

Drugs

Powder of aripiprazole (Tamin pharmaceutical investment company, Iran) was dissolved in tween 80 and administrated IP to mice.

Treatment

Mice were randomly divided into four groups, including; Control (n=11), tween 80 as vehicle (n=16), aripiprazole 10 mg/kg (n=17), and aripiprazole 20 mg/kg (n=18). The mice were inoculated IP with 0.5 ml of mice brain suspension containing 50 tissue cysts.

Vehicle and aripiprazole were injected one day after inoculation of parasites and every other day for the first ten days and every two days until the end of the first month. Control mice did not receive any drugs.

At the end of the second month after inoculation, the mice were anesthetized with intraperitoneal injections of ketamine/xylazine (60 mg/kg and 6 mg/kg, respectively). Mice were sacrificed under anesthesia, and their brains were quickly removed. Then, brain homogenate was provided separately from whole brain of each mouse in 2 ml of saline. The number of cysts was counted in smears prepared from 200 µl of brain homogenate with 100× and 400× magnifications of optical microscope.

Data analysis

For normalizing the initial data, natural logarithm transformation was used. Data analysis was through Kolmogorov-Smirnov test, Analysis of Variance (ANOVA) and Tukey *post hoc*. A level of $P < 0.05$ was considered significant.

Results

In our study, some of the mice died in weeks 1–3 after inoculation of brain suspension containing tissue cysts. Ten mice in each group were randomly examined for counting *T. gondii* brain cysts. Overall, the cysts were observed in brains of all mice;




Figure 1. Mean±SEM logarithm of brain cysts numbers of *Toxoplasma gondii* in 200 µl of brain homogenate in different treatment groups of mice

however, there was a remarkably intra-group and inter-group variation in numbers of cysts (Table 1).

As the numbers of cysts varied, the data was normalized. Normalized data analysis showed no significant difference between mean±SEM of brain cyst numbers in the two doses of aripiprazole compared to the control and vehicle groups, which is shown on a logarithmic scale in Figure 1.

Discussion

In our study, aripiprazole had no inhibitory effect on brain cystogenesis of *T. gondii* *in vivo*. The results corresponds with results of Goodwin *et al* who showed valproic acid is ineffective on brain cysts of *T. gondii* in mice (10). On the other hand, these findings are inconsistent with *in vitro* results of other studies (6, 11) which showed valproic acid has an inhibitory effect against tachyzoites of *T. gondii* in cell culture. In other studies of Goodwin *et al*, thioridazine and fluphenazine decreased proliferation of *T. gondii* tachyzoites *in vitro* (7).

Experimentally and clinically, anti-*Toxoplasma* effect of anti-psychotic drugs has not been demonstrated to date. There is a main difference in design of our study and Goodwin *et al* (10). In the present study, aripiprazole was injected in acute phase of infection in order to prevent tissue cystogenesis in mice, whereas, they administered valproic acid orally in latent phase of infection for elimination of the tissue cysts. In the acute phase of *toxoplasma* infection, the bradyzoites convert to rapidly dividing tachyzoites that are sensitive to the anti-*Toxoplasma* drugs. In contrast, in the latent phase of infection, the proliferative tachyzoites converted to slowly dividing bradyzoites enclosed by cyst wall, which can persist for long-time in host tissue and are impervious against the anti-*Toxoplasma* drugs. Therefore, evidence obtained in our study is a strong support for the results of the previous study (10): anti-psychotic drugs have no anti-*Toxoplasma* effect *in vivo*. Also, brain cystogenesis capacity of *T. gondii* shows a remarkable variation in mice experimentally infected with this parasite, as observed in the present study and others (12).

The mechanism of action of anti-toxoplasmosis drugs is established. But, this mechanism about anti-psychotic drugs is unclear. In this study, we have used aripiprazole, an atypical anti-psychotic drug, which unlike typical anti-psychotic drugs, is a partial D₂-receptor agonist and also has therapeutic efficacy through its 5-HT_{2A} antagonism and possibly 5-HT_{1A} partial agonism (13).

On the other hand, an increase in intracellular calcium occurs in tachyzoites of *T. gondii* when they attach to their host cells and this increase is required for invasion. Based on the results, it seems that initial attachment of tachyzoites to host cells is followed by calcium signaling (14) and this interaction was also inhibited by calcium channel blockers (verapamil) and calmodulin antagonists such as trifluoperazine and calmidazolium (15). Previously, it was reported that clozapine as a prototype agent in the atypical class, was not calmodulin antagonist and it is suggested that some of its action may be dependent on calmodulin-activated kinase activity (7, 16).

Furthermore, clozapine in protecting host cell against tachyzoites of *T. gondii* was not effective *in vitro* (7). It is possible that aripiprazole similar to clozapine is not antagonist of calmodulin to inhibit entry of tachyzoites to host cells. On the other hand, the mechanism of clozapine and aripiprazole in the atypical group are not same. It was shown that the ratio of affinity for D₂ receptors to affinity for 5-HT_{2A} receptors for aripiprazole is medium and this ratio for clozapine is very low (16). Also, in contrast to clozapine, aripiprazole as a blocker of 5-HT_{2A} receptors could reduce intracellular Ca²⁺ levels in rat pituitary cell line (17). Thus, it seems that aripiprazole with chemical structure of dihydrocarbostyryl has different effects on Ca²⁺ intracellular.

Conclusion

Results show that aripiprazole groups could not decrease the brain cystogenesis. Further studies need to clear the role of differently structured anti-psychotic drugs in treatment of *T. gondii*.

Acknowledgment

This work was supported by Qazvin University of Medical Sciences. The authors are thankful to the Vice Chancellor of Research of Qazvin University of Medical Sciences for their financial support. The authors are kindly appreciate Dr H Keshavarz, and Dr S Shojaee, Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences for preparing an avirulent Tehran strain of *T. gondii*. The results reported in this paper were part of the thesis of N Samadzadeh.

References

1. Montoya JG, Boothroyd JC, Kovacs JA. *Toxoplasma gondii*. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 3495-3526.
2. Dubey JP. Tissue cyst tropism in *Toxoplasma gondii*: a comparison of tissue cyst formation in organs of cats, and rodents fed oocysts. *Parasitology* 1997; 115:15-20.
3. Torrey EF, Bartko JJ, Yolken RH. *Toxoplasma gondii* and other risk factors for schizophrenia: an update. *Schizophr Bull* 2012; 38:642-647.
4. Flegr J. Influence of latent *Toxoplasma* infection on human personality, physiology and morphology: pros and cons of the *Toxoplasma*-human model in studying the manipulation hypothesis. *J Exp Biol* 2013; 216:127-133.
5. Stibbs HH. Changes in brain concentrations of catecholamines and indoleamines in *Toxoplasma gondii* infected mice. *Ann Trop Med Parasitol* 1985; 79: 153-157.
6. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of *Toxoplasma gondii*. *Schizophr Res* 2003; 62:237-244.
7. Goodwin DG, Strobl JS, Lindsay DS. Evaluation of five antischizophrenic agents against *Toxoplasma gondii* in human cell cultures. *J Parasitol* 2011; 97:148-151.
8. Asgari Q, Keshavarz H, Shojaee S, Motazedian MH, Mohebbi M, Miri R, *et al*. *In vitro* and *in vivo* potential of RH strain of *Toxoplasma gondii* (Type I) in tissue cyst forming. *Iran J Parasitol* 2013; 8:367-375.
9. Ghorbani M, Samii AH. Toxoplasmic lymphadenitis in Iran. *J Trop Med Hyg* 1973; 76:158-160.
10. Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. *J Parasitol* 2008; 94:555-557.
11. Strobl JS, Cassell M, Mitchell SM, Reilly CM, Lindsay DS. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors

with potent anti-*Toxoplasma gondii* activity *in vitro*. J Parasitol 2007; 93:694-700.

12. Berenreiterová M, Flegr J, Kuběna AA, Němec P. The distribution of *Toxoplasma gondii* cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PLoS One 2011; 6:e28925.

13. Meltzer H. Anti-psychotic Agents and Lithium. In: Katzung BG, Masters SB and Trevor AJ, Editors. Basic and clinical pharmacology. New York: McGraw-Hill; 2010. p. 362-383.

14. Vieira MC, Moreno SN. Mobilization of intracellular calcium upon attachment of *Toxoplasma gondii* tachyzoites to human fibroblasts is required for invasion. Mol Biochem Parasitol 2000; 106:157-162.

15. Pezzella-D'Alessandro N, Le Moal H, Bonhomme

A, Valere A, Klein C, Gomez-Marin J, *et al*. Calmodulin distribution and the actomyosin cytoskeleton in *Toxoplasma gondii*. J Histochem Cytochem 2001; 49:445-454.

16. Ninan I, Jardemark KE, Liang X, Wang RY. Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 2003; 47:285-294.

17. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, *et al*. Interaction of the novel anti-psychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and *in vivo* electrophysiological studies. Psychopharmacology (Berl) 2007; 190:373-382.